[Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment].
257 patients from 33 centres were involved in a six-month study, the aim of which was to assess the effect of orlistat together with a diet. The authors examined how the treatment effected the anthropometrical and lipid parameters, extending the study to the aspect of paraoxonase activity in case of 25 patients. 44 patients dropped out during the study period due to the lack of sufficient diet compliance, whereas 3 patients had to stop the therapy because of the adverse event of flatus with discharge. On the average, the body mass of the patients decreased from 100.8 +/- 18.9 to 91.3 +/- 18.6 kg, i.e. by 9.5 kgs, while their BMI was reduced from 36.1 +/- 5.6 to 32.5 +/- 5.2 kg/m2 and the circumference of the waist changing from 119.1 +/- 20 to 108.3 +/- 15.1 cm, i.e. by 10.8 cms. The blood sugar level significantly decreased from 5.7 to 5.4, while the cholesterol concentration significantly dropped from 5.9 to 5.5, the triglyceride level being reduced from 2.4 to 2.1 mmol/l and blood pressure falling significantly from 136.6/86.9 to 129.9/81.6. All the above changes showed a significant decrease. However, the HDL-cholesterol level did not change. The serum paraoxonase activity significantly increased (143 +/- 49 vs 166 +/- 43 UL) along with the standardised values for HDL (PON/HDL), even compared to the control diet group. From the above results it may be concluded that orlistat tends to have an antioxidant effect.
Audikovszky
M
M
Fóvárosi Szent Imre Kórház IV, sz. Belgyógyászati Osztály.
Pados
G
G
Seres
I
I
Harangi
M
M
Fülöp
P
P
Katona
E
E
Winkler
G
G
Paragh
G
G
D000005:Abdomen; D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D043303:Aryldialkylphosphatase; D015992:Body Mass Index; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D004038:Diet, Reducing; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004950:Esterases / Q000378:metabolism*; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008049:Lipase / Q000037:antagonists & inhibitors*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism*; D000077403:Orlistat; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D019440:Anti-Obesity Agents; D004791:Enzyme Inhibitors; D007783:Lactones; D008055:Lipids; D014280:Triglycerides; D000077403:Orlistat; D002784:Cholesterol; D004950:Esterases; D008049:Lipase; D043303:Aryldialkylphosphatase